The Serine/Threonine Protein Kinase TBK1 pipeline drugs market research report outlays comprehensive information on the Serine/Threonine Protein Kinase TBK1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Serine/Threonine Protein Kinase TBK1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Gastrointestinal, Oncology, and Infectious Disease which include the indications Autoimmune Disorders, Systemic Lupus Erythematosus, Inflammatory Bowel Disease, Liver Fibrosis, Lung Cancer, Prostate Cancer, and Unspecified Infectious Diseases. It also reviews key players involved in Serine/Threonine Protein Kinase TBK1 targeted therapeutics development with respective active and dormant or discontinued products.
The Serine/Threonine Protein Kinase TBK1 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 2, and 1 respectively.
Serine/Threonine Protein Kinase TBK1 overview
Serine/Threonine Protein Kinase TBK1 is crucial for regulating inflammatory responses to foreign agents. Upon toll-like receptor activation by viral or bacterial components, it associates with TRAF3 and TANK. It phosphorylates interferon regulatory factors (IRFs) IRF3 and IRF7, along with DDX3X. This activity facilitates subsequent homodimerization and nuclear translocation of the IRFs, leading to the transcriptional activation of pro-inflammatory and antiviral genes, including IFNA and IFNB. Its key role in IRF3 activation involves phosphorylating innate adapter proteins MAVS, STING1, and TICAM1 on their pLxIS motif, recruiting IRF3 and licensing it for phosphorylation by TBK1. Additionally, it restrains bacterial proliferation by phosphorylating the autophagy receptor OPTN/Optineurin on ‘Ser-177’, enhancing LC3 binding affinity and promoting antibacterial autophagy.
For a complete picture of Serine/Threonine Protein Kinase TBK1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
